ARWR has some interesting subsidiaries.<g>
The stock has been on a near term DT since Oct 19 when it started to drop from apparent support at the $5 level
bigcharts.marketwatch.com
Its longer term DT dates from its June H at $7.69
bigcharts.marketwatch.com
It seems the stock is worth to be put on a WL & may be OK to start a small position at present levels.
bigcharts.marketwatch.com
ARWR business is in the identification, development, and commercialization of nanotechnology-related products.
Its subsidiary, Insert Therapeutics, has developed Cyclosert, a proprietary drug delivery platform technology based on a nano-engineered class of linear cyclodextrin-containing polymers.
Its IT-101,is an anti-cancer drug candidate under PI for ovarian Ca.,NSLC, pancreatic & solid tumors.
clinicaltrials.gov
Another subsidiary, Calando Pharmaceuticals, Inc., focuses on the design, development, and commercialization of RNAi therapeutics to treat diseases by combining RNAi therapeutics with patented delivery technologies. Its CALAA-01 combines its delivery technology with a siRNA duplex targeting the M2 subunit of ribonucleotide reductase.
It has been designed for intravenous injection. Upon delivery to the target cell, the targeting ligand binds to membrane receptors on the cell surface and the RNA-containing nanoparticle is taken into the cell by endocytosis.
The chemistry built into the polymer functions to unpackage the siRNA from the delivery vehicle.(The polymer and siRNA self-assemble into nanoparticles of approximately 50 nm diameter that fully protect the siRNA from nuclease degradation in serum.)
In addition to targeting tumors, the targeting of liver cells has also been accomplished in vivo. Using anti-FAS siRNA, liver targeted delivery from tail vein injections in mice are able to provide FAS gene inhibition like that observed from a high pressure tail vein injection that is not clinically relevant.
It selected Agilent Technologies to manufacture the active siRNA component in its CALAA01.
webwire.com
Its other subsidiary, Unidym, Inc., also focuses on the application of carbon-based materials, such as touch screens, flat panel displays, and solid state lightings to the electronics industry.
And its other subsidiary, Aonex Technologies, Inc., is developing semiconductor nanomaterials, such as engineered wafers that comprise thin films of materials suitable for LED fabrication. It has a collaboration agreement with R&D-Biopharmaceuticals GmbH to develop and commercialize conjugates of the potent anti-cancer compound tubulysin.
As previously mentioned, ARWR seems to have several interesting subsidiaries.<g> The company was founded in 2003 in Pasadena CA & don't expect to see an IPO of any of the subsidiaries in the near future.<g>
ARWR has no signidicant LTD, the short position has increased lately & is around 14x its ADV.
The insider & institutions reportedly hold > 30% each. (Some of the well known institutions hold a significant amount of the float.<g>)
finance.yahoo.com
At any rate ARWR has had its ups & downs in the past, but with its interesting subsidiaries, the R/R looks OK at present levels.(Caveat: I just decided to start a small position.<g>)
bigcharts.marketwatch.com
Its Chairman and CEO, R. Bruce Stewart,will present at Global Crown Capital’s Nanotechnology Investment Conference in Frisco on Thursday.
Bernard |
